Linked to EAHP Statements
Section 1 – Introductory Statements and Governance: Statements 1.1., 1.3, 1.6
Section 2 – Selection, Procurement and Distribution: Statements 2.1, 2.3, 2.4
Section 4 – Clinical Pharmacy Services: Statements 4.1
Section 5 – Patient Safety and Quality Assurance: Statement 5.11
ACPE UAN: 0475-0000-18-006-L04-P. A knowledge based activity.
For many years, biological drugs have not been subject to the competition of generics. There are good reasons for this, as complex biological molecules cannot be shown to be bioequivalent based solely on analytical data and pharmacokinetic studies.
Now is the time for cancer drugs. Biosimilars of blockbuster drugs that are key therapeutic options in several types of cancer will be coming to the market soon, such as rituximab, cetuximab or trastuzumab. The opportunity for savings is huge, biological drugs may account for half the cancer drugs budget, but these drugs will be used in life threatening diseases and this may lead to some concerns.
To make the best of this new frontier, Hospital Pharmacists must understand the concepts and facts, to be able to provide a scientific, unbiased approach to this issue, with a focus on patient care in a world of limited resources.
At the end of the seminar participants should be able to:
- Acquire new understanding of the key facts which support biosimilar approval in the EU as applied to cancer therapy;
- Recognise biased trends of change in first line therapy; and,
- Advise how to implement biosimilars of monoclonal antibodies used in cancer therapy.